001     143882
005     20240229112611.0
024 7 _ |a 10.1002/ijc.32481
|2 doi
024 7 _ |a pmid:31135957
|2 pmid
024 7 _ |a 0020-7136
|2 ISSN
024 7 _ |a 1097-0215
|2 ISSN
037 _ _ |a DKFZ-2019-01444
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Schmitt, Katrin
|b 0
245 _ _ |a Somatic mutations and promotor methylation of the ryanodine receptor 2 is a common event in the pathogenesis of head and neck cancer.
260 _ _ |a Bognor Regis
|c 2019
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1637569319_12566
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Genomic sequencing projects unraveled the mutational landscape of head and neck squamous cell carcinoma (HNSCC) and provided a comprehensive catalogue of somatic mutations. However, the limited number of significant cancer-related genes obtained so far only partially explains the biological complexity of HNSCC and hampers the development of novel diagnostic biomarkers and therapeutic targets. We pursued a multi-scale omics approach based on whole-exome sequencing, global DNA methylation and gene expression profiling data derived from tumor samples of the HIPO-HNC cohort (n=87), and confirmed new findings with datasets from The Cancer Genome Atlas (TCGA). Promoter methylation was confirmed by MassARRAY analysis and protein expression was assessed by immunohistochemistry and immunofluorescence staining. We discovered a set of cancer-related genes with frequent somatic mutations and high frequency of promoter methylation. This included the ryanodine receptor 2 (RYR2), which showed variable promoter methylation and expression in both tumor samples and cell lines. Immunohistochemical staining of tissue sections unraveled a gradual loss of RYR2 expression from normal mucosa via dysplastic lesion to invasive cancer, and indicated that reduced RYR2 expression in adjacent tissue and precancerous lesions might serve as risk factor for unfavorable prognosis and upcoming malignant conversion. In summary, our data indicate that impaired RYR2 function by either somatic mutation or epigenetic silencing is a common event in HNSCC pathogenesis. Detection of RYR2 expression and/or promoter methylation might enable risk assessment for malignant conversion of dysplastic lesions. This article is protected by copyright. All rights reserved.
536 _ _ |a 315 - Imaging and radiooncology (POF3-315)
|0 G:(DE-HGF)POF3-315
|c POF3-315
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Molfenter, Britta
|b 1
700 1 _ |a Koerich Laureano, Natalia
|0 P:(DE-He78)b36816550a92f3d43063316f4ab83d2e
|b 2
700 1 _ |a Tawk, Bouchra
|0 P:(DE-He78)4f5721350bd23340e626cb0340bef47a
|b 3
700 1 _ |a Bieg, Matthias
|0 P:(DE-He78)e247efc0264a7b0e4bae09804002d4e1
|b 4
700 1 _ |a Pastor Hostench, Xavier
|0 P:(DE-He78)d0227eb1849a4009d6b361aacc22c907
|b 5
700 1 _ |a Weichenhan, Dieter
|0 P:(DE-He78)ff4024f7bc236e7897d9c18ee19c451f
|b 6
700 1 _ |a Ullrich, Nina D
|b 7
700 1 _ |a Shang, Viny
|b 8
700 1 _ |a Richter, Daniela
|0 P:(DE-He78)29306fd3ae9f1a9839ed888ebc5c8074
|b 9
700 1 _ |a Stögbauer, Fabian
|b 10
700 1 _ |a Schroeder, Lea
|0 P:(DE-He78)b12aaacaa142dabed85c6d84d00bf0fb
|b 11
700 1 _ |a de Bem Prunes, Bianca
|b 12
700 1 _ |a Visioli, Fernanda
|b 13
700 1 _ |a Varvaki Rados, Pantelis
|b 14
700 1 _ |a Jou, Adriana
|b 15
700 1 _ |a Plath, Michaela
|b 16
700 1 _ |a Federspil, Philippe A
|b 17
700 1 _ |a Thierauf, Julia
|b 18
700 1 _ |a Döscher, Johannes
|b 19
700 1 _ |a Weissinger, Stephanie E
|b 20
700 1 _ |a Hoffmann, Thomas K
|b 21
700 1 _ |a Wagner, Steffen
|0 0000-0003-0873-1601
|b 22
700 1 _ |a Wittekindt, Claus
|b 23
700 1 _ |a Ishaque, Naveed
|0 P:(DE-He78)4096eeffdfc73b75e8ba63dc621a017d
|b 24
700 1 _ |a Eils, Roland
|0 P:(DE-He78)78b6aa82148e60b4d91e3a37a6d3d9a0
|b 25
700 1 _ |a Klussmann, Jens P
|b 26
700 1 _ |a Holzinger, Dana
|0 P:(DE-He78)d84ca2cd7f160904c387ee699735076c
|b 27
700 1 _ |a Plass, Christoph
|0 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
|b 28
700 1 _ |a Abdollahi, Amir
|0 P:(DE-He78)360c5bc2b71a849e35aca747c041dda7
|b 29
700 1 _ |a Freier, Kolja
|b 30
700 1 _ |a Weichert, Wilko
|0 P:(DE-He78)891da714b7f7991d9c4c1d5224c991e7
|b 31
|u dkfz
700 1 _ |a Zaoui, Karim
|b 32
700 1 _ |a Hess, Jochen
|0 P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f
|b 33
|e Last author
773 _ _ |a 10.1002/ijc.32481
|g p. ijc.32481
|0 PERI:(DE-600)1474822-8
|n 12
|p 3299-3310
|t International journal of cancer
|v 145
|y 2019
|x 1097-0215
909 C O |p VDB
|o oai:inrepo02.dkfz.de:143882
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)b36816550a92f3d43063316f4ab83d2e
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)4f5721350bd23340e626cb0340bef47a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)e247efc0264a7b0e4bae09804002d4e1
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)d0227eb1849a4009d6b361aacc22c907
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)ff4024f7bc236e7897d9c18ee19c451f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)29306fd3ae9f1a9839ed888ebc5c8074
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)b12aaacaa142dabed85c6d84d00bf0fb
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)4096eeffdfc73b75e8ba63dc621a017d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 25
|6 P:(DE-He78)78b6aa82148e60b4d91e3a37a6d3d9a0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 27
|6 P:(DE-He78)d84ca2cd7f160904c387ee699735076c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 28
|6 P:(DE-He78)4301875630bc997edf491c694ae1f8a9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 29
|6 P:(DE-He78)360c5bc2b71a849e35aca747c041dda7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 31
|6 P:(DE-He78)891da714b7f7991d9c4c1d5224c991e7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 33
|6 P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-315
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Imaging and radiooncology
|x 0
914 1 _ |y 2019
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J CANCER : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J CANCER : 2017
920 1 _ |0 I:(DE-He78)A102-20160331
|k A102
|l Molekulare Grundlagen von HNO-Tumoren
|x 0
920 1 _ |0 I:(DE-He78)E210-20160331
|k E210
|l E210 Translationale Radioonkologie
|x 1
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 2
920 1 _ |0 I:(DE-He78)B080-20160331
|k B080
|l Theoretische Bioinformatik
|x 3
920 1 _ |0 I:(DE-He78)B370-20160331
|k B370
|l Epigenomik
|x 4
920 1 _ |0 I:(DE-He78)B340-20160331
|k B340
|l Translationale Medizinische Onkologie
|x 5
920 1 _ |0 I:(DE-He78)F022-20160331
|k F022
|l Infektionen und Krebs-Epidemiologie
|x 6
920 1 _ |0 I:(DE-He78)F020-20160331
|k F020
|l Infektionen und Krebs-Epidemiologie
|x 7
920 1 _ |0 I:(DE-He78)L701-20160331
|k L701
|l DKTK München
|x 8
920 1 _ |0 I:(DE-He78)E221-20160331
|k E221
|l E221 AG Molekulare Grundlagen von HNO-Tumoren
|x 9
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A102-20160331
980 _ _ |a I:(DE-He78)E210-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)B080-20160331
980 _ _ |a I:(DE-He78)B370-20160331
980 _ _ |a I:(DE-He78)B340-20160331
980 _ _ |a I:(DE-He78)F022-20160331
980 _ _ |a I:(DE-He78)F020-20160331
980 _ _ |a I:(DE-He78)L701-20160331
980 _ _ |a I:(DE-He78)E221-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21